TALWIN 50
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN 50 is an oral small-molecule tablet approved in 1969 by Sanofi. The generic name and mechanism of action are not currently available in this dataset. The drug's exact indications require clarification from additional sources.
LOE Approaching
Product approaching loss of exclusivity with low commercial job velocity signals potential team downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for TALWIN 50. Working on this legacy product offers experience in mature/declining asset management, cost containment, and generic transition strategy—valuable for career development in market access or product lifecycle roles.
Brand ManagerProduct Manager
Worked on TALWIN 50 at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.